For the historian of early modern Italian architecture, Vitruvius is unavoidable. In fifteenth- and sixteenth-century Italy, the study of Vitruvius, in conjunction with the surviving physical models of ancient buildings, was a project that united architects. With the difficult tract as their guide, architects teamed together, often with learned aides, to understand the principles of ancient design. Comparing Vitruvian dicta with antiquarian fragments, architects endeavored to recreate the forms, numbers, and proportional rules prescribed by the ancient author. And using pencil, charcoal, and ink, they created images, filling in the voids of the famously unillustrated text.

The NIH-Moderna mRNA COVID-19 vaccine’s steep price increase raises concerns that this will be the new anchor for continued price hikes and underscores the need for upstream government intervention to enable greater accountability and stewardship of public biomedical research investment.

This article discusses the misalignment of the drug innovation model in the US with broader societal goals. The paper calls for a reconfiguration of this model to prioritize the common good and ensure equitable access to health innovations. The article stresses the importance of adopting a mission-oriented approach to shape the drug market, including reforming intellectual property rights.

We are witnessing increasing partisan polarization across the world. It is often argued that partisan “echo chambers” are one of the drivers of both policy and affective polarization. In this article, we develop and test the argument that the political homogeneity of people’s social environment shapes polarization. Using an innovative, large-scale pre-registered “lab-in-the-field” experiment in the United Kingdom, we examine how polarization is influenced by partisan group homogeneity. We recruit nationally representative partisans and assign them to discuss a salient policy issue, either with like-minded partisans (an echo chamber) or in a mixed-partisan group. This allows us to examine how group composition affects polarization. In line with our expectations, we find that partisan echo chambers increase both policy and affective polarization compared to mixed discussion groups. This has important implications for our understanding of the drivers of polarization and for how out-group animosity might be ameliorated in the mass public.

Health systems are integrating medical-legal partnerships (MLPs) into clinical care and increasingly center “complex care” patients. These patients have intersecting medical and social needs and often face systemic inequities that exacerbate their chronic health conditions. This paper describes a role for MLPs in hospital quality initiatives; examines the ethics of MLPs assisting with guardianship and institutionalization of hospital patients including marginalized groups; and advocates for MLP interventions designed to address intersectional and ethical concerns.

This special JLME symposium addresses ways that federal policy can incentivize innovation in medical therapeutics and make pharmaceuticals more financially accessible.

Just like the Sun, other stars also exhibit differential rotation. Currently, the rotation profile of a star that hosts a transiting planet can be estimated if during a transits, the planet occults a spot on the photosphere of the star, causing slight variations in its light curve. By detecting the same spot during a later transit, the stellar rotation period at that latitude is determined. Here, we present the results of differential rotation for 48 stars, 13 from the spot transit mapping method, while the remaining 35 stars from other techniques. The results show that the differential rotation is correlated with the stellar mean rotation period for fast rotating stars and strongly anti-correlated for slow rotators. The transition occuring at rotation period of 5 days. On the other hand, the differential shear increases with effective temperature for fast rotating stars, but the correlation is lost for the slow rotators.

Kesselheim proposes doubling the NIH’s budget to promote clinically meaningful pharmaceutical innovation. Since the effects of a previous doubling (from 1998-2003) were mixed, I argue that policymakers should couple future budget growth with investments in experimentation and evaluation.